These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study. Rollé A; Vidal E; Laguette P; Garnier Y; Delta D; Martino F; Portecop P; Etienne-Julan M; Piednoir P; De Jong A; Romana M; Bernit E Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138299 [No Abstract] [Full Text] [Related]
4. Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease. De Franceschi L; Mura P; Schweiger V; Vencato E; Quaglia FM; Delmonte L; Evangelista M; Polati E; Olivieri O; Finco G Pain Pract; 2016 Jul; 16(6):680-7. PubMed ID: 26009799 [TBL] [Abstract][Full Text] [Related]
5. An innovative short-stay health care model for treatment of uncomplicated vaso-occlusive crisis in adult sickle cell disease patients in Canada to reduce emergency department utilization. Binding A; Ward R; Phua C; Naessens V; O'Brien T; Bhatia S; Baranek H; Marani H; Mukerji G CJEM; 2019 Jan; 21(1):55-62. PubMed ID: 29039292 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis. Shah SP; Twilla JD; Kemp L; Phelps GL; Reaves A J Pain Palliat Care Pharmacother; 2018 Dec; 32(4):201-207. PubMed ID: 30896312 [TBL] [Abstract][Full Text] [Related]
7. State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease. Puri L; Nottage KA; Hankins JS; Anghelescu DL Paediatr Drugs; 2018 Feb; 20(1):29-42. PubMed ID: 28853040 [TBL] [Abstract][Full Text] [Related]
8. Lactate Dehydrogenase: A Marker of the Severity of Vaso-Occlusive Crisis in Children with Sickle Cell Disease Presenting at the Emergency Department. García-Morin M; López-Sangüos C; Vázquez P; Alvárez T; Marañón R; Huerta J; Cela E Hemoglobin; 2016 Nov; 40(6):388-391. PubMed ID: 28361592 [TBL] [Abstract][Full Text] [Related]
9. Use of a clinical pathway to improve the acute management of vaso-occlusive crisis pain in pediatric sickle cell disease. Ender KL; Krajewski JA; Babineau J; Tresgallo M; Schechter W; Saroyan JM; Kharbanda A Pediatr Blood Cancer; 2014 Apr; 61(4):693-6. PubMed ID: 24249617 [TBL] [Abstract][Full Text] [Related]
10. IF IM in a crisis: Intranasal fentanyl versus intravenous morphine in adult vaso-occlusive crisis. Assad O; Zamora R; Brown K; Melnitsky L; Moses J; Sherman V Am J Emerg Med; 2023 Feb; 64():86-89. PubMed ID: 36481614 [TBL] [Abstract][Full Text] [Related]
11. Safety of an ED High-Dose Opioid Protocol for Sickle Cell Disease Pain. Tanabe P; Martinovich Z; Buckley B; Schmelzer A; Paice JA J Emerg Nurs; 2015 May; 41(3):227-35. PubMed ID: 25241635 [TBL] [Abstract][Full Text] [Related]
12. Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies. Coyne KS; Currie BM; Callaghan M; Wyrwich KW; Pease S; Baker CL; Arkin S; Pittman DD Eur J Haematol; 2022 Sep; 109(3):226-237. PubMed ID: 35569114 [TBL] [Abstract][Full Text] [Related]
13. Timing of opioid administration as a quality indicator for pain crises in sickle cell disease. Mathias MD; McCavit TL Pediatrics; 2015 Mar; 135(3):475-82. PubMed ID: 25667245 [TBL] [Abstract][Full Text] [Related]
14. IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Dampier CD; Smith WR; Wager CG; Kim HY; Bell MC; Miller ST; Weiner DL; Minniti CP; Krishnamurti L; Ataga KI; Eckman JR; Hsu LL; McClish D; McKinlay SM; Molokie R; Osunkwo I; Smith-Whitley K; Telen MJ; Clin Trials; 2013 Apr; 10(2):319-31. PubMed ID: 23539110 [TBL] [Abstract][Full Text] [Related]
15. Patient-Controlled Analgesia vs Intravenous Push Hydromorphone for Pain Management of Vaso-Occlusive Crisis Associated With Sickle Cell Disease. Russo K; Chhunchha P J Pain Palliat Care Pharmacother; 2023 Jun; 37(2):116-122. PubMed ID: 36701332 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of sex disparities in opioid use among ED patients with sickle cell disease, 2006-2015. Wilson TT; Chou SC; Becker S; Schuur JD; Beaudoin F Am J Emerg Med; 2021 Dec; 50():597-601. PubMed ID: 34592567 [TBL] [Abstract][Full Text] [Related]
17. Regional anesthesia for sickle cell disease vaso-occlusive crisis: A single-center case series. Karsenty C; Tubman VN; Liu CJ; Fasipe T; Wyatt KEK Pediatr Blood Cancer; 2022 Jun; 69(6):e29695. PubMed ID: 35373913 [TBL] [Abstract][Full Text] [Related]
18. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study. Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574 [No Abstract] [Full Text] [Related]
19. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study. Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602 [TBL] [Abstract][Full Text] [Related]
20. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. van Beers EJ; van Tuijn CF; Nieuwkerk PT; Friederich PW; Vranken JH; Biemond BJ Am J Hematol; 2007 Nov; 82(11):955-60. PubMed ID: 17617790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]